Skip NavigationSkip to Content

Bone marrow cell homing to sites of acute tibial fracture: Zr-89-oxine cell labeling with positron emission tomographic imaging in a mouse model

  1. Author:
    Asiedu, Kingsley O.
    Ferdousi, Munira
    Ton, Phuongnga T.
    Adler,Stephen
    Choyke, Peter L.
    Sato, Noriko
  2. Author Address

    NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bldg 10,Room B3B406, Bethesda, MD 20892 USA.NCI, Clin Monitoring Res Program Directorate, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
    1. Year: 2018
    2. Date: Dec 13
    3. Epub Date: 2018 12 13
  1. Journal: EJNMMI RESEARCH
  2. SPRINGEROPEN,
    1. 8
    2. 1
  3. Type of Article: Article
  4. Article Number: 109
  5. ISSN: 2191-219X
  1. Abstract:

    BackgroundBone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. In this study, we employed zirconium-89 (Zr-89)-oxine-labeled BM cells imaged with positron emission tomography (PET)/computed tomography (CT) to visualize and quantitate BM cell trafficking following acute bone injury and to investigate the effect of plerixafor on BM cell homing. Unilateral 1-mm incisions were created in the distal tibia of mice either on the same day (d0) or 24h (d1) after Zr-89-oxine-labeled BM cell transfer (n=4-6, 2-2.3x10(7) cells at 9.65-15.7kBq/10(6) cells). Serial microPET/CT imaging was performed and migration of Zr-89-labeled cells to the bone injury was quantified. The effects of three daily doses of plerixafor on cell trafficking were evaluated beginning on the day of fracture generation (n=4-6). The labeled cells localizing to the fracture were analyzed by flow cytometry and immunohistochemistry.ResultsIn d0- and d1-fracture groups, 0.7% and 1.7% of administered BM cells accumulated within the fracture, respectively. Plerixafor treatment reduced BM cell migration to the fracture by approximately one-third (p< 0.05 for both fracture groups). Flow cytometry analysis of donor cells collected from the injured site revealed a predominance of CD45(+) stem/progenitor cell populations and subsequent histological analysis demonstrated the presence of donor cells engrafted within sites of fracture repair.Conclusion(89)Zr-oxine labeling enabled visualization and quantitation of BM cell recruitment to acute fractures and further demonstrated that plerixafor plays an inhibitory role in this recruitment.

    See More

External Sources

  1. DOI: 10.1186/s13550-018-0463-8
  2. PMID: 30547233
  3. PMCID: PMC6292830
  4. WOS: 000453259300001

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel